cabozantinib + vemurafenib

Cabozantinib + vemurafenib is a combination therapy investigated for the treatment of BRAF-mutant metastatic or unresectable solid tumors and melanoma. Cabozantinib is a multi-tyrosine kinase inhibitor that targets MET, VEGFR2, and AXL, which are involved in tumor growth, angiogenesis, and resistance to BRAF inhibition. Vemurafenib is a selective inhibitor of the mutated BRAF V600E kinase, a key driver in the MAPK signaling pathway. By combining these agents, the therapy aims to achieve more robust inhibition of tumor cell proliferation and overcome MET-mediated resistance mechanisms that often limit the efficacy of BRAF inhibitor monotherapy. This combination is primarily being evaluated in clinical trials sponsored by the National Cancer Institute (NCI).

Other names

cabozantinib-s-malate + vemurafenib